tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2020 Nov 9;7(11)
faa528.
doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020
Anna M Acosta[SUP] 1 [/SUP], Adria L Mathis[SUP] 1 2 [/SUP], Daniel S Budnitz[SUP] 1 3 [/SUP], Andrew I Geller[SUP] 1 3 [/SUP], Shua J Chai[SUP] 3 4 5 [/SUP], Nisha B Alden[SUP] 6 [/SUP], James Meek[SUP] 7 [/SUP], Evan J Anderson[SUP] 8 9 10 [/SUP], Patricia Ryan[SUP] 11 [/SUP], Sue Kim[SUP] 12 [/SUP], Kathryn Como-Sabetti[SUP] 13 [/SUP], Salina Torres[SUP] 14 [/SUP], Elizabeth Dufort[SUP] 15 [/SUP], Nancy M Bennett[SUP] 16 [/SUP], Laurie M Billing[SUP] 17 [/SUP], Melissa Sutton[SUP] 18 [/SUP], H Keipp Talbot[SUP] 19 [/SUP], Andrea George[SUP] 20 [/SUP], Huong Pham[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Alicia Fry[SUP] 1 3 [/SUP], Shikha Garg[SUP] 1 3 [/SUP], Lindsay Kim[SUP] 1 3 [/SUP]
Affiliations
Abstract
Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
Keywords: coronavirus; hospitalization; therapeutics.
. 2020 Nov 9;7(11)
faa528.doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020
Anna M Acosta[SUP] 1 [/SUP], Adria L Mathis[SUP] 1 2 [/SUP], Daniel S Budnitz[SUP] 1 3 [/SUP], Andrew I Geller[SUP] 1 3 [/SUP], Shua J Chai[SUP] 3 4 5 [/SUP], Nisha B Alden[SUP] 6 [/SUP], James Meek[SUP] 7 [/SUP], Evan J Anderson[SUP] 8 9 10 [/SUP], Patricia Ryan[SUP] 11 [/SUP], Sue Kim[SUP] 12 [/SUP], Kathryn Como-Sabetti[SUP] 13 [/SUP], Salina Torres[SUP] 14 [/SUP], Elizabeth Dufort[SUP] 15 [/SUP], Nancy M Bennett[SUP] 16 [/SUP], Laurie M Billing[SUP] 17 [/SUP], Melissa Sutton[SUP] 18 [/SUP], H Keipp Talbot[SUP] 19 [/SUP], Andrea George[SUP] 20 [/SUP], Huong Pham[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Alicia Fry[SUP] 1 3 [/SUP], Shikha Garg[SUP] 1 3 [/SUP], Lindsay Kim[SUP] 1 3 [/SUP]
Affiliations
- PMID: 33274249
- PMCID: PMC7686662 (available on 2021-11-09)
- DOI: 10.1093/ofid/ofaa528
Abstract
Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
Keywords: coronavirus; hospitalization; therapeutics.